Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I agree. If MNTA and MYL were hypothetically to receive FDA approval for Copaxone on the same day, I think MNTA’s share price would finish the day lower than it started. That said, I don’t expect MYL to receive approval as quickly as MNTA.